Horien Biochemical Technology CoROCO:7814 -6.53%21 EBITDA Margin % is 27.70% as of Dec. 2025, which is 79% above its 10-year median of 15.48. GuruFocus rates ROCO:7814 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, Horien Biochemical Technology Co ranks better than 86.2% on this metric.
Horien Biochemical Technology Co (ROCO:7814) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Horien Biochemical Technology Co EBITDA Margin % Related Terms
Horien Biochemical Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horien Biochemical Technology Co EBITDA Margin % Chart
ROCO:7814 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Horien Biochemical Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Horien Biochemical Technology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Horien Biochemical Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Horien Biochemical Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horien Biochemical Technology Co (ROCO:7814) has a EBITDA Margin % of 27.70% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Horien Biochemical Technology Co and its competitors. This is 79% above median its historical median of 15.48. Over the past decade, Horien Biochemical Technology Co's EBITDA Margin % has ranged from 4.48 to 30.85. According to the industry distribution chart, Horien Biochemical Technology Co ranks #130 out of 942 companies in the Biotechnology industry, placing it in the top 13.8%.
Is Horien Biochemical Technology Co's EBITDA Margin % too high?
Horien Biochemical Technology Co's current EBITDA Margin % of 27.70% is 79% above median its 10-year median of 15.48. Over the past 10 years, this metric has ranged from a low of 4.48 to a high of 30.85. Based on the distribution chart, Horien Biochemical Technology Co ranks #130 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Horien Biochemical Technology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Horien Biochemical Technology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Horien Biochemical Technology Co ranks #130 out of 942 companies for EBITDA Margin %. This places Horien Biochemical Technology Co in the top 14% of its industry — outperforming the majority of peers. Historically, Horien Biochemical Technology Co's own EBITDA Margin % has ranged from 4.48 to 30.85 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Horien Biochemical Technology Co and its competitors. Horien Biochemical Technology Co's current EBITDA Margin % is 27.70%, which is 79% above median its own 10-year median of 15.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Horien Biochemical Technology Co stock overvalued right now?
Horien Biochemical Technology Co (ROCO:7814) has a current EBITDA Margin % of 27.70%. The current EBITDA Margin % is 27.70%, which is 79% above median its 10-year median of 15.48. Horien Biochemical Technology Co's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Horien Biochemical Technology Co (ROCO:7814), the current EBITDA Margin % is 27.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Horien Biochemical Technology Co Business Description
Horien Biochemical Technology Co Ltd is engaged in the research and development of cosmetic raw materials and medical devices and facilities. The products of the company include Gen-Nusis, skin repairment ingredients, PeptioMax, the latest cosmetic raw material, Lifkin, and other substitutes used in dentistry and general surgery.
21GF Score
Get the complete analysis for ROCO:7814
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7814 has been successfully added to your 